Photo of Sarah J. Hill,  MD, PhD

Sarah J. Hill, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 272-5451
Fax: (617) 272-5451


sarah_hill@dfci.harvard.edu

Sarah J. Hill, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Pathology, Harvard Medical School
  • Member of the Faculty, Medical Oncology, Dana-Farber Cancer Institute
  • Associate Pathologist, Pathology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The mission of the Hill Lab is to develop a deep mechanistic understanding of ovarian cancer development and progression which we will harness to make ovarian cancer a more manageable disease for all patients through the development of effective methods of early detection, more personalized treatment, and better therapeutic strategies.

In pursuit of this mission, the Hill lab focuses on understanding the role of the DNA damage response in ovarian carcinogenesis, tumor evolution, the anti-tumor immune response, and therapeutic sensitivity and resistance.

We utilize molecular and cellular biology, immunology, sequencing, and imaging techniques in ovarian cancer cell lines, patient-derived normal and ovarian cancer organoids, and ovarian cancer mouse models.

Publications

Powered by Harvard Catalyst
  • Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, Matulonis UA, Cannistra SA, Dizon DS. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol 2019. PubMed
  • Hill SJ, D'Andrea AD. Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids. 2019; 9:828-830. PubMed
  • Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids. 2018. PubMed
  • Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, Eggan K, Livingston DM. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc Natl Acad Sci U S A 2016; 113:E7701-E7709. PubMed
  • Hatchi E, Skourti-Stathaki K, Ventz S, Pinello L, Yen A, Kamieniarz-Gdula K, Dimitrov S, Pathania S, McKinney KM, Eaton ML, Kellis M, Hill SJ, Parmigiani G, Proudfoot NJ, Livingston DM. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol Cell 2015; 57:636-47. PubMed
  • Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014; 34:3828-42. PubMed
  • Hill SJ, Rolland T, Adelmant G, Xia X, Owen MS, Dricot A, Zack TI, Sahni N, Jacob Y, Hao T, McKinney KM, Clark AP, Reyon D, Tsai SQ, Joung JK, Beroukhim R, Marto JA, Vidal M, Gaudet S, Hill DE, Livingston DM. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev 2014; 28:1957-75. PubMed